Abstract

Numerous studies have suggested that the dynamics of ctDNA during neoadjuvant therapy in early breast cancer have consequences for prognosis. Still, each study's small number of participants prevents drawing firm conclusions. We aimed to determine the predictive value of liquid biopsy in predicting the outcome of patients with early-stage breast cancer following neoadjuvant therapy.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call